Definition of Cmin by EMEA [Regulatives / Guidelines]

posted by Ravi  – India, 2010-03-13 13:05 (5530 d 20:58 ago) – Posting: # 4910
Views: 24,533

Dear All,

According to Overview of comments received on draft Guideline on the investigation of bioequivalence by EMEA Cmin,ss is defined as "By Cmin,ss we mean the concentration at the end of the dosage interval, i.e. Ctrough".
But according to WinNonlin User guide Cmin at steady state is defined as "Minimum concentration between dose time and dose time + Tau".

Now my question is Which definition is to be followed. What is the exact definition of Cmin according to other regulatory bodies (e.g. FDA, Health Canada, ANVISA). If definition by EMEA is to be followed then we can not use Cmin value calculated by using WinNonlin for submission. Please correct me if I am wrong.

Waiting for your reply.

Thanks & Regards
Ravi Pandey

Complete thread:

UA Flag
Activity
 Admin contact
23,424 posts in 4,927 threads, 1,667 registered users;
73 visitors (0 registered, 73 guests [including 9 identified bots]).
Forum time: 11:03 CEST (Europe/Vienna)

Patients may recover in spite of drugs or because of them.    John Gaddum

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5